Login / Signup

Genome Editing and Human Pluripotent Stem Cell Technologies for in vitro Monogenic Diabetes Modeling.

Yosef Tsegaye DabiSisay Teka Degechisa
Published in: Diabetes, metabolic syndrome and obesity : targets and therapy (2022)
Diabetes is a metabolic disease characterized by chronic hyperglycemia. Polygenic diabetes, which encompasses type-1 and type-2 diabetes, is the most prevalent kind of diabetes and is caused by a combination of different genetic and environmental factors, whereas rare phenotype monogenic diabetes is caused by a single gene mutation. Monogenic diabetes includes Neonatal diabetes mellitus and Maturity-onset diabetes of the young. The majority of our current knowledge about the pathogenesis of diabetes stems from studies done on animal models. However, the genetic difference between these creatures and humans makes it difficult to mimic human clinical pathophysiology, limiting their value in modeling key aspects of human disease. Human pluripotent stem cell technologies combined with genome editing techniques have been shown to be better alternatives for creating in vitro models that can provide crucial knowledge about disease etiology. This review paper addresses genome editing and human pluripotent stem cell technologies for in vitro monogenic diabetes modeling.
Keyphrases
  • type diabetes
  • glycemic control
  • genome editing
  • crispr cas
  • cardiovascular disease
  • stem cells
  • endothelial cells
  • induced pluripotent stem cells
  • metabolic syndrome
  • adipose tissue
  • skeletal muscle
  • dna methylation